-
Stifel Reiterates Buy Rating on Nyxoah SA (NYXH)
-
Nyxoah stock surges after FDA approves Genio system for sleep apnea
-
Cantor Fitzgerald Reiterates Overweight Rating on Nyxoah SA (NYXH)
-
Stifel Reiterates Buy Rating on Nyxoah SA (NYXH)
-
Piper Sandler Highlights Top Medtech Picks and Catalyst-Rich Names
-
Cantor Fitzgerald Reiterates Overweight Rating on Nyxoah SA (NYXH)
-
Nyxoah SA (NYXH) PT Lowered to $14 at Stifel
-
Oppenheimer Reiterates Outperform Rating on Nyxoah SA (NYXH)
-
Stifel Reiterates Buy Rating on Nyxoah SA (NYXH)
-
Cantor Fitzgerald newsletter says Elutia best, Anteris worst performer
-
Nyxoah SA (NYXH) PT Lowered to $15 at Stifel
-
H.C. Wainwright Reiterates Buy Rating on Nyxoah SA (NYXH)
-
Piper Sandler on HGNS Devices Following Eli Lilly's Zepbound FDA Indication Approval
-
Oppenheimer Reiterates Outperform Rating on Nyxoah SA (NYXH)
-
Nyxoah SA (NYXH) PT Lowered to $17 at H.C. Wainwright
-
H.C. Wainwright Reiterates Buy Rating on Nyxoah SA (NYXH)
-
Stifel Reiterates Buy Rating on Nyxoah SA (NYXH)
-
H.C. Wainwright Reiterates Buy Rating on Nyxoah SA (NYXH)

